Literature DB >> 12628722

A novel missense mutation in the myosin binding protein-C gene is responsible for hypertrophic cardiomyopathy with left ventricular dysfunction and dilation in elderly patients.

Tetsuo Konno1, Masami Shimizu, Hidekazu Ino, Toru Matsuyama, Masato Yamaguchi, Hidenobu Terai, Kenshi Hayashi, Tomohito Mabuchi, Masaru Kiyama, Kenji Sakata, Tatsumi Hayashi, Masaru Inoue, Tomoya Kaneda, Hiroshi Mabuchi.   

Abstract

OBJECTIVES: We studied the clinical features of hypertrophic cardiomyopathy (HCM) caused by a novel mutation in the myosin binding protein-C (MyBP-C) gene in patients and family members of Japanese descent.
BACKGROUND: Previous reports have demonstrated that the clinical features of HCM associated with mutations in the MyBP-C gene include late onset and a favorable clinical course. Recently, some mutations in genes encoding sarcomeric proteins have been reported to be a cause of dilated cardiomyopathy (DCM), as well as HCM. However, mutations of the MyBP-C gene have not been reported as a cause of DCM up to now.
METHODS: We analyzed MyBP-C gene mutations in 250 unrelated probands with HCM and in 90 with DCM. We used electrocardiography (ECG) and echocardiography to determine clinical phenotypes.
RESULTS: We identified 17 individuals in 8 families (7 HCM, 1 DCM) with an Arg820Gln mutation in the MyBP-C gene. Overall, 2 (40%) of 5 carriers age >70 years displayed "burnt-out" phase HCM, and one of them had been diagnosed as having DCM before genetic identification. The disease penetrance in subjects age >50 years was 70% by echocardiography and 100% by ECG, and that in those age <50 years was 40% and 50%, respectively.
CONCLUSIONS: Elderly patients with Arg820Gln mutation may show "burnt-out" phase HCM, and patients with this mutation may be included among those diagnosed as having DCM. Screening of patients with DCM, as well as HCM, for this mutation is of significant importance because patients with this mutation may be diagnosed clinically as having DCM.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12628722     DOI: 10.1016/s0735-1097(02)02957-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  15 in total

Review 1.  The genetic basis of hypertrophic cardiomyopathy in cats and humans.

Authors:  Mark D Kittleson; Kathryn M Meurs; Samantha P Harris
Journal:  J Vet Cardiol       Date:  2015-12       Impact factor: 1.701

Review 2.  Sarcomeric protein mutations in dilated cardiomyopathy.

Authors:  Audrey N Chang; James D Potter
Journal:  Heart Fail Rev       Date:  2005-09       Impact factor: 4.214

Review 3.  Risk stratification in hypertrophic cardiomyopathy.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; S Kachboura
Journal:  Herz       Date:  2018-04-25       Impact factor: 1.443

4.  Dissociation of structural and functional phenotypes in cardiac myosin-binding protein C conditional knockout mice.

Authors:  Peter P Chen; Jitandrakumar R Patel; Patricia A Powers; Daniel P Fitzsimons; Richard L Moss
Journal:  Circulation       Date:  2012-07-24       Impact factor: 29.690

5.  Genotypic effect of a mutation of the MYBPC3 gene and two phenotypes with different patterns of inheritance.

Authors:  Nejat Mahdieh; Maryam Hosseini Moghaddam; Mahsa Motavaf; Ahmad Rabbani; Mahdieh Soveizi; Majid Maleki; Bahareh Rabbani; Azin Alizadeh-Asl
Journal:  J Clin Lab Anal       Date:  2018-03-01       Impact factor: 2.352

Review 6.  In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament.

Authors:  Samantha P Harris; Ross G Lyons; Kristina L Bezold
Journal:  Circ Res       Date:  2011-03-18       Impact factor: 17.367

Review 7.  Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects.

Authors:  Masa-aki Kawashiri; Kenshi Hayashi; Tetsuo Konno; Noboru Fujino; Hidekazu Ino; Masakazu Yamagishi
Journal:  Heart Vessels       Date:  2013-08-02       Impact factor: 2.037

8.  Large-scale mutation screening in patients with dilated or hypertrophic cardiomyopathy: a pilot study using DGGE.

Authors:  Raphael Zeller; Boris T Ivandic; Philipp Ehlermann; Oliver Mücke; Christian Zugck; Andrew Remppis; Evangelos Giannitsis; Hugo A Katus; Dieter Weichenhan
Journal:  J Mol Med (Berl)       Date:  2006-05-20       Impact factor: 4.599

9.  Impact of QT variables on clinical outcome of genotyped hypertrophic cardiomyopathy.

Authors:  Katsuharu Uchiyama; Kenshi Hayashi; Noboru Fujino; Tetsuo Konno; Yuichiro Sakamoto; Kenji Sakata; Masa-aki Kawashiri; Hidekazu Ino; Masakazu Yamagishi
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-01       Impact factor: 1.468

Review 10.  Personalized medicine for cardiovascular diseases.

Authors:  Hayato Tada; Noboru Fujino; Akihiro Nomura; Chiaki Nakanishi; Kenshi Hayashi; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  J Hum Genet       Date:  2020-08-08       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.